期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 29, 期 12, 页码 601-608出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2008.08.005
关键词
-
资金
- Monash University Postgraduate Publications Award
- National Health and Medical Research Council
- B.K.K-H (Australia)
Until recently, most of the biological effects of nitric oxide (NO) have been attributed to its uncharged state (NO degrees), yet NO can also exist in the reduced state as nitroxyl (HNO or NO-). Putatively generated from both NO synthase (NOS)-dependent and -independent sources, HNO is rapidly emerging as a novel entity with distinct pharmacology and therapeutic advantages over its redox sibling, NO degrees. Thus, unlike NO degrees HNO can target cardiac sarcoplasmic ryanodine receptors to increase myocardial contractility, can interact directly with thiols and is resistant to both scavenging by superoxide (degrees O-2(-)) and tolerance development. HNO donors are protective in the setting of heart failure in which NO degrees donors have minimal impact. Here, we discuss the unique pharmacology of HNO versus NO degrees and highlight the therapeutic potential of HNO donors in the treatment of cardiovascular disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据